{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:20:46Z","timestamp":1780143646271,"version":"3.54.0"},"reference-count":40,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Many drugs can induce liver injury; however, vaccine-induced liver injury is a rare phenomenon. SARS-CoV-2 messenger RNA (mRNA) vaccines are now widely administered, and clinical evidence of liver injury has been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To characterize the histologic features of SARS-CoV-2 mRNA vaccine\u2013associated liver injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Thirteen liver biopsies from 12 patients with elevated liver enzymes clinically favored to be secondary to SARS-CoV-2 mRNA vaccine were identified between 2021 and 2022. Demographics, clinical information, and histologic features of liver biopsies were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>All patients (median age, 58 years; M:F = 4:8) received at least 1 dose of SARS-CoV-2 mRNA vaccines (7 Pfizer and 5 Moderna). Four patients had a history of liver disease. Nine patients developed symptoms between 1 day and 2 months after receiving the vaccine dose. Viral serologies were negative. Drug-induced liver injury was thought to be less likely clinically in the 3 patients who had started new medications. Autoimmune antibodies were detected in 9 patients. Moderate to severe active hepatitis was the dominant histologic pattern of injury (9 of 13 biopsies; 69%). Resolving hepatitis, cholestatic hepatitic injury, and bile duct injury were identified in 1 biopsy each. All patients recovered spontaneously or with steroid therapy, except one patient who developed autoimmune hepatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Moderate to severe active hepatitis is commonly observed in SARS-CoV-2 mRNA vaccine\u2013associated liver injury, and female patients may be more susceptible to injury. Liver injury resolves spontaneously or with steroid treatment. In rare cases, these vaccines may trigger an underlying immune condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0095-oa","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T03:35:57Z","timestamp":1725852957000},"page":"556-560","source":"Crossref","is-referenced-by-count":1,"title":["Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines"],"prefix":"10.5858","volume":"149","author":[{"given":"Rebecca C.","family":"Obeng","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio (Obeng, Xue)"},{"name":"the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio (Obeng)"},{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio (Obeng, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Escobar","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Escobar, Vadasz, Ju, Yang, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Vadasz","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Escobar, Vadasz, Ju, Yang, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia (Zheng)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Ju","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Escobar, Vadasz, Ju, Yang, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Booth","sequence":"additional","affiliation":[{"name":"the Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri (Booth)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Escobar, Vadasz, Ju, Yang, Xue)"},{"name":"the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Yang, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Al Diffalha","sequence":"additional","affiliation":[{"name":"the Department of Pathology, University of Alabama Heersink School of Medicine, Birmingham (Al Diffalha, Dhall)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Dhall","sequence":"additional","affiliation":[{"name":"the Department of Pathology, University of Alabama Heersink School of Medicine, Birmingham (Al Diffalha, Dhall)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Westerhoff","sequence":"additional","affiliation":[{"name":"the Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan (Westerhoff)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xue","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio (Obeng, Xue)"},{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio (Obeng, Xue)"},{"name":"the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Escobar, Vadasz, Ju, Yang, Xue)"},{"name":"the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Yang, Xue)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"11","key":"i1543-2165-149-6-556-b01","series-title":"Nat Rev Drug Discov","first-page":"817","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","unstructured":"Chaudhary\n              N\n            ,\nWeissmanD,\nWhiteheadKA.\n          mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817\u2013838."},{"issue":"11","key":"i1543-2165-149-6-556-b02","series-title":"N Engl J Med","first-page":"1011","article-title":"Covid-19 vaccines\u2014immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","unstructured":"Barouch\n              DH.\n            \n          \n          Covid-19 vaccines\u2014immunity, variants, boosters. N Engl J Med. 2022;387(11):1011\u20131020."},{"key":"i1543-2165-149-6-556-b03","series-title":"BMJ","first-page":"n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","unstructured":"Lopez Bernal\n              J\n            ,\nAndrewsN,\nGowerC, et al.\n          Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088."},{"key":"i1543-2165-149-6-556-b04","series-title":"BMJ","first-page":"n2244","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study","volume":"374","author":"Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox\n              J\n            ,\nCouplandCA,\nMehtaN, et al.\n          Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244."},{"issue":"4","key":"i1543-2165-149-6-556-b05","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"118","article-title":"Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults\u2014United States, August\u2013December 2021","volume":"71","author":"Tenforde","year":"2022","unstructured":"Tenforde\n              MW\n            ,\nPatelMM,\nGaglaniM, et al.\n          Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults\u2014United States, August\u2013December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118\u2013124."},{"issue":"20","key":"i1543-2165-149-6-556-b06","series-title":"JAMA","first-page":"2043","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","unstructured":"Tenforde\n              MW\n            ,\nSelfWH,\nAdamsK, et al.\n          Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043\u20132054."},{"issue":"14","key":"i1543-2165-149-6-556-b07","series-title":"JAMA","first-page":"1427","article-title":"Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines","volume":"328","author":"Kelly","year":"2022","unstructured":"Kelly\n              JD\n            ,\nLeonardS,\nHoggattKJ, et al.\n          Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA. 2022;328(14):1427\u20131437."},{"issue":"7","key":"i1543-2165-149-6-556-b08","series-title":"JAMA","first-page":"639","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","unstructured":"Accorsi\n              EK\n            ,\nBrittonA,\nFleming-DutraKE, et al.\n          Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639\u2013651."},{"issue":"9","key":"i1543-2165-149-6-556-b09","series-title":"Hepatol Commun","first-page":"2513","article-title":"Immune-mediated liver injury following COVID-19 vaccination: a systematic review","volume":"6","author":"Roy","year":"2022","unstructured":"Roy\n              A\n            ,\nVermaN,\nSinghS,\nPradhanP,\nTanejaS,\nSinghM.\n          Immune-mediated liver injury following COVID-19 vaccination: a systematic review. Hepatol Commun. 2022;6(9):2513\u20132522."},{"issue":"6","key":"i1543-2165-149-6-556-b10","series-title":"Hepatology","first-page":"1576","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","volume":"76","author":"Efe","year":"2022","unstructured":"Efe\n              C\n            ,\nKulkarniAV,\nTerziroli Beretta-PiccoliB, et al.\n          Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022;76(6):1576\u20131586."},{"issue":"1","key":"i1543-2165-149-6-556-b11","series-title":"JHEP Rep","first-page":"100605","article-title":"Histological and serological features of acute liver injury after SARS-CoV-2 vaccination","volume":"5","author":"Codoni","year":"2023","unstructured":"Codoni\n              G\n            ,\nKirchnerT,\nEngelB, et al.\n          Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2023;5(1):100605."},{"issue":"5","key":"i1543-2165-149-6-556-b12","series-title":"J Hepatol","first-page":"1339","article-title":"Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines","volume":"77","author":"Wong","year":"2022","unstructured":"Wong\n              CKH\n            ,\nMakLY,\nAuICH, et al.\n          Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77(5):1339\u20131348."},{"issue":"3","key":"i1543-2165-149-6-556-b13","series-title":"Hepatol Forum","first-page":"97","article-title":"Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination","volume":"3","author":"Patel","year":"2022","unstructured":"Patel\n              AH\n            ,\nAminR,\nLalosAT.\n          Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination. Hepatol Forum. 2022;3(3):97\u201399. 36177105"},{"issue":"1","key":"i1543-2165-149-6-556-b14","series-title":"J Hepatol","first-page":"211","article-title":"Liver injury following SARS-CoV-2 vaccination: a multicenter case series","volume":"76","author":"Shroff","year":"2022","unstructured":"Shroff\n              H\n            ,\nSatapathySK,\nCrawfordJM,\nToddNJ,\nVanWagnerLB.\n          Liver injury following SARS-CoV-2 vaccination: a multicenter case series. J Hepatol. 2022;76(1):211\u2013214."},{"issue":"12","key":"i1543-2165-149-6-556-b15","series-title":"Vaccines (Basel)","first-page":"10","article-title":"Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence","author":"Trontzas","year":"2022","unstructured":"Trontzas\n              IP\n            ,\nKyriakoulisKG,\nVathiotisIA, et al.\n          Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines (Basel). 2022;10(12)."},{"issue":"2","key":"i1543-2165-149-6-556-b16","series-title":"World J Virol","first-page":"100","article-title":"Immune-mediated liver injury following COVID-19 vaccination","volume":"12","author":"Schinas","year":"2023","unstructured":"Schinas\n              G\n            ,\nPolyzouE,\nDimakopoulouV,\nTsoupraS,\nGogosC,\nAkinosoglouK.\n          Immune-mediated liver injury following COVID-19 vaccination. World J Virol. 2023;12(2):100\u2013108."},{"issue":"1","key":"i1543-2165-149-6-556-b17","series-title":"J Hepatol","first-page":"222","article-title":"Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty","volume":"75","author":"Bril","year":"2021","unstructured":"Bril\n              F\n            ,\nAl DiffalhaS,\nDeanM,\nFettigDM.\n          Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021;75(1):222\u2013224."},{"issue":"10","key":"i1543-2165-149-6-556-b18","series-title":"Cureus","first-page":"e30304","article-title":"COVID-19 vaccination-induced cholangiopathy and autoimmune hepatitis: a series of two cases","volume":"14","author":"Zafar","year":"2022","unstructured":"Zafar\n              M\n            ,\nGordonK,\nMackenL, et al.\n          COVID-19 vaccination-induced cholangiopathy and autoimmune hepatitis: a series of two cases. Cureus. 2022;14(10):e30304."},{"issue":"4","key":"i1543-2165-149-6-556-b19","series-title":"J Hepatol","first-page":"1209","article-title":"Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination","volume":"77","author":"Lee","year":"2022","unstructured":"Lee\n              SK\n            ,\nKwonJH,\nYoonN,\nLeeSH,\nSungPS.\n          Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination. J Hepatol. 2022;77(4):1209\u20131211."},{"issue":"3","key":"i1543-2165-149-6-556-b20","series-title":"J Hepatol","first-page":"666","article-title":"Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics","volume":"79","author":"Uzun","year":"2023","unstructured":"Uzun\n              S\n            ,\nZinnerCP,\nBeenenAC, et al.\n          Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics. J Hepatol. 2023;79(3):666\u2013676."},{"issue":"11","key":"i1543-2165-149-6-556-b01","series-title":"Nat Rev Drug Discov","first-page":"817","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","unstructured":"Chaudhary\n              N\n            ,\nWeissmanD,\nWhiteheadKA.\n          mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817\u2013838."},{"issue":"11","key":"i1543-2165-149-6-556-b02","series-title":"N Engl J Med","first-page":"1011","article-title":"Covid-19 vaccines\u2014immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","unstructured":"Barouch\n              DH.\n            \n          \n          Covid-19 vaccines\u2014immunity, variants, boosters. N Engl J Med. 2022;387(11):1011\u20131020."},{"key":"i1543-2165-149-6-556-b03","series-title":"BMJ","first-page":"n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","unstructured":"Lopez Bernal\n              J\n            ,\nAndrewsN,\nGowerC, et al.\n          Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088."},{"key":"i1543-2165-149-6-556-b04","series-title":"BMJ","first-page":"n2244","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study","volume":"374","author":"Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox\n              J\n            ,\nCouplandCA,\nMehtaN, et al.\n          Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244."},{"issue":"4","key":"i1543-2165-149-6-556-b05","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"118","article-title":"Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults\u2014United States, August\u2013December 2021","volume":"71","author":"Tenforde","year":"2022","unstructured":"Tenforde\n              MW\n            ,\nPatelMM,\nGaglaniM, et al.\n          Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults\u2014United States, August\u2013December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):118\u2013124."},{"issue":"20","key":"i1543-2165-149-6-556-b06","series-title":"JAMA","first-page":"2043","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","unstructured":"Tenforde\n              MW\n            ,\nSelfWH,\nAdamsK, et al.\n          Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326(20):2043\u20132054."},{"issue":"14","key":"i1543-2165-149-6-556-b07","series-title":"JAMA","first-page":"1427","article-title":"Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines","volume":"328","author":"Kelly","year":"2022","unstructured":"Kelly\n              JD\n            ,\nLeonardS,\nHoggattKJ, et al.\n          Incidence of severe COVID-19 illness following vaccination and booster with BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines. JAMA. 2022;328(14):1427\u20131437."},{"issue":"7","key":"i1543-2165-149-6-556-b08","series-title":"JAMA","first-page":"639","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants","volume":"327","author":"Accorsi","year":"2022","unstructured":"Accorsi\n              EK\n            ,\nBrittonA,\nFleming-DutraKE, et al.\n          Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639\u2013651."},{"issue":"9","key":"i1543-2165-149-6-556-b09","series-title":"Hepatol Commun","first-page":"2513","article-title":"Immune-mediated liver injury following COVID-19 vaccination: a systematic review","volume":"6","author":"Roy","year":"2022","unstructured":"Roy\n              A\n            ,\nVermaN,\nSinghS,\nPradhanP,\nTanejaS,\nSinghM.\n          Immune-mediated liver injury following COVID-19 vaccination: a systematic review. Hepatol Commun. 2022;6(9):2513\u20132522."},{"issue":"6","key":"i1543-2165-149-6-556-b10","series-title":"Hepatology","first-page":"1576","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","volume":"76","author":"Efe","year":"2022","unstructured":"Efe\n              C\n            ,\nKulkarniAV,\nTerziroli Beretta-PiccoliB, et al.\n          Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022;76(6):1576\u20131586."},{"issue":"1","key":"i1543-2165-149-6-556-b11","series-title":"JHEP Rep","first-page":"100605","article-title":"Histological and serological features of acute liver injury after SARS-CoV-2 vaccination","volume":"5","author":"Codoni","year":"2023","unstructured":"Codoni\n              G\n            ,\nKirchnerT,\nEngelB, et al.\n          Histological and serological features of acute liver injury after SARS-CoV-2 vaccination. JHEP Rep. 2023;5(1):100605."},{"issue":"5","key":"i1543-2165-149-6-556-b12","series-title":"J Hepatol","first-page":"1339","article-title":"Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines","volume":"77","author":"Wong","year":"2022","unstructured":"Wong\n              CKH\n            ,\nMakLY,\nAuICH, et al.\n          Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77(5):1339\u20131348."},{"issue":"3","key":"i1543-2165-149-6-556-b13","series-title":"Hepatol Forum","first-page":"97","article-title":"Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination","volume":"3","author":"Patel","year":"2022","unstructured":"Patel\n              AH\n            ,\nAminR,\nLalosAT.\n          Acute liver injury and IgG4-related autoimmune pancreatitis following mRNA-based COVID-19 vaccination. Hepatol Forum. 2022;3(3):97\u201399. 36177105"},{"issue":"1","key":"i1543-2165-149-6-556-b14","series-title":"J Hepatol","first-page":"211","article-title":"Liver injury following SARS-CoV-2 vaccination: a multicenter case series","volume":"76","author":"Shroff","year":"2022","unstructured":"Shroff\n              H\n            ,\nSatapathySK,\nCrawfordJM,\nToddNJ,\nVanWagnerLB.\n          Liver injury following SARS-CoV-2 vaccination: a multicenter case series. J Hepatol. 2022;76(1):211\u2013214."},{"issue":"12","key":"i1543-2165-149-6-556-b15","series-title":"Vaccines (Basel)","first-page":"10","article-title":"Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence","author":"Trontzas","year":"2022","unstructured":"Trontzas\n              IP\n            ,\nKyriakoulisKG,\nVathiotisIA, et al.\n          Vaccine-related autoimmune hepatitis: emerging association with SARS-CoV-2 vaccination or coincidence? Vaccines (Basel). 2022;10(12)."},{"issue":"2","key":"i1543-2165-149-6-556-b16","series-title":"World J Virol","first-page":"100","article-title":"Immune-mediated liver injury following COVID-19 vaccination","volume":"12","author":"Schinas","year":"2023","unstructured":"Schinas\n              G\n            ,\nPolyzouE,\nDimakopoulouV,\nTsoupraS,\nGogosC,\nAkinosoglouK.\n          Immune-mediated liver injury following COVID-19 vaccination. World J Virol. 2023;12(2):100\u2013108."},{"issue":"1","key":"i1543-2165-149-6-556-b17","series-title":"J Hepatol","first-page":"222","article-title":"Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty","volume":"75","author":"Bril","year":"2021","unstructured":"Bril\n              F\n            ,\nAl DiffalhaS,\nDeanM,\nFettigDM.\n          Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021;75(1):222\u2013224."},{"issue":"10","key":"i1543-2165-149-6-556-b18","series-title":"Cureus","first-page":"e30304","article-title":"COVID-19 vaccination-induced cholangiopathy and autoimmune hepatitis: a series of two cases","volume":"14","author":"Zafar","year":"2022","unstructured":"Zafar\n              M\n            ,\nGordonK,\nMackenL, et al.\n          COVID-19 vaccination-induced cholangiopathy and autoimmune hepatitis: a series of two cases. Cureus. 2022;14(10):e30304."},{"issue":"4","key":"i1543-2165-149-6-556-b19","series-title":"J Hepatol","first-page":"1209","article-title":"Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination","volume":"77","author":"Lee","year":"2022","unstructured":"Lee\n              SK\n            ,\nKwonJH,\nYoonN,\nLeeSH,\nSungPS.\n          Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination. J Hepatol. 2022;77(4):1209\u20131211."},{"issue":"3","key":"i1543-2165-149-6-556-b20","series-title":"J Hepatol","first-page":"666","article-title":"Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics","volume":"79","author":"Uzun","year":"2023","unstructured":"Uzun\n              S\n            ,\nZinnerCP,\nBeenenAC, et al.\n          Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics. J Hepatol. 2023;79(3):666\u2013676."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/6\/article-p556.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/6\/556\/3519123\/i1543-2165-149-6-556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/6\/article-p556.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/6\/article-p556.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:13:54Z","timestamp":1770772434000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/6\/article-p556.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":40,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0095-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}